These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
291 related items for PubMed ID: 12857554
1. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Steegmann JL, Moreno G, Aláez C, Osorio S, Granda A, de la Cámara R, Arranz E, Reino FG, Salvanés FR, Fernández-Rañada JM, Muñoz C. Haematologica; 2003 Jul; 88(7):762-8. PubMed ID: 12857554 [Abstract] [Full Text] [Related]
2. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418 [Abstract] [Full Text] [Related]
5. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD. Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563 [Abstract] [Full Text] [Related]
14. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate. Fugazza G, Miglino M, Bruzzone R, Quintino S, Gatti AM, Grasso R, Gobbi M, Frassoni F, Sessarego M. J Exp Clin Cancer Res; 2004 Jun 15; 23(2):295-9. PubMed ID: 15354415 [Abstract] [Full Text] [Related]
15. [Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha]. Molnár L, Nagy A, Dávid M, Szomor A, Méhes G, Kovács G, Losonczy H. Orv Hetil; 2004 Apr 25; 145(17):901-7. PubMed ID: 15170967 [Abstract] [Full Text] [Related]
16. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, Díaz-Mediavilla J, Sierra J. Haematologica; 2003 Nov 25; 88(11):1213-20. PubMed ID: 14607749 [Abstract] [Full Text] [Related]
18. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res; 2006 Dec 15; 12(24):7374-9. PubMed ID: 17189410 [Abstract] [Full Text] [Related]
19. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia]. Voglová J, Poznarová A, Chrobák L, Rabasová J, Beránek M, Moravcová J, Faber E, Klamová H, Cikhart M. Vnitr Lek; 2004 Jan 15; 50(1):21-3, 26-9. PubMed ID: 15015226 [Abstract] [Full Text] [Related]
20. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response. Usman M, Syed NN, Kakepoto GN, Adil SN, Khurshid M. J Assoc Physicians India; 2007 Feb 15; 55():103-7. PubMed ID: 17571738 [Abstract] [Full Text] [Related] Page: [Next] [New Search]